Revival Gold Announces Strategic Placement with EMR Capital and C$24 Million Capital Raise
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES OF AMERICA OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES OR THE DISTRICT OF COLUMBIA.
TORONTO, July 10, 2025 (GLOBE NEWSWIRE) -- Revival Gold Inc. (TSXV:RVG) ("Revival Gold" or the "Company") is pleased to announce that it has agreed to purchase with EMR Capital Management Limited ("EMR") pursuant to which EMR has agreed to purchase 28,506,250 common shares of the Company (the "Common Shares") at a price of C$0.48 per Common Share for gross proceeds of US$10 million (C$13.68 million) (the "EMR Strategic Placement").
EMR is a specialist resources private equity manager and operator with extensive operational experience and a proven track record in successful resource operations, development and investment. EMR's pro-forma interest in Revival Gold on closing is expected to amount to approximately 10.86% assuming the Concurrent Offering is fully subscribed and there are no other Common Share issuances. In connection with the EMR Strategic Placement, EMR will be granted customary anti-dilution rights to maintain its equity ownership interest and the right to nominate a director to Revival Gold's Board of Directors pursuant to an investor rights agreement to be entered into between EMR and Revival Gold.
"EMR has developed a world class reputation backing proven management teams to deliver value creation in the global mining industry," said Hugh Agro, President & CEO. "The addition of EMR to Revival Gold's roster has paved the way to a significant cash injection into the business and secures a strong financial partner with whom the Company can advance towards future gold production," added Agro.
In addition to the EMR Strategic Placement, the Company announces its intention to complete a non-brokered private placement of up to C$10.32 million by the issuance of up to a maximum of 21,493,750 Common Shares at a price of C$0.48 per Common Share (the "Concurrent Offering").
Subject to compliance with applicable regulatory requirements and in accordance with Part 5A of National Instrument 45-106, Prospectus Exemptions ("NI 45-106" and with Part 5A, the "Listed Issuer Financing Exemption"), the Common Shares offered under the Concurrent Offering will be offered for sale to purchasers resident in Canada (except Quebec) and are expected to be immediately freely tradeable under applicable Canadian securities legislation if sold to purchasers' resident in Canada. The Common Shares sold under the Concurrent Offering may also be issued to purchasers outside of Canada, including to purchaser's resident in the United States and in certain offshore foreign jurisdictions, pursuant to applicable regulatory requirements and in accordance with OSC Rule 72-503 - Distributions Outside Canada ("OSC Rule 72-503"). The Common sold to purchasers in the United States will be made on a private placement basis pursuant to one or more exemptions from registration requirements of the United States Securities Act of 1933, as amended (the "U.S. Securities Act"). Purchasers are advised to consult their own legal advisors in this regard.
The Common Shares issued pursuant to the EMR Strategic Placement will be offered pursuant to the accredited investor exemption under NI 45-106 and will be subject to a 4-month and one day hold period under applicable Canadian securities laws. The net proceeds from the EMR Strategic Placement and Concurrent Offering will be ...
